X4 PHARMACEUTICALS, INC Revenue
X4 PHARMACEUTICALS, INC (XFOR) reported Revenue of $2.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Revenue
us-gaap:Revenues · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC revenues for the quarter ending 2026-06-30 was $2.40M, a 41.18% increase year-over-year.
- X4 PHARMACEUTICALS, INC revenues for the quarter ending 2026-03-31 was $2.50M, a 177.78% increase year-over-year.
- X4 PHARMACEUTICALS, INC revenues for the quarter ending 2025-12-31 was $2.20M, a 46.67% increase year-over-year.
- X4 PHARMACEUTICALS, INC revenues for the quarter ending 2025-09-30 was $1.57M, a 179.64% increase year-over-year.
- X4 PHARMACEUTICALS, INC revenues for fiscal 2025 was $6.50M, a 150.00% increase from fiscal 2024.
- X4 PHARMACEUTICALS, INC revenues for fiscal 2024 was $2.60M.
- X4 PHARMACEUTICALS, INC revenues for fiscal 2023 was $0.00.
| Period end | Revenues 3 month | Revenues 3 month as first filed | Revenues 6 month | Revenues 6 month as first filed | Revenues 9 month | Revenues 9 month as first filed | Revenues 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.40M 10-Q · filed 2026-08-06 | $4.80M 10-Q · filed 2026-08-06 | $7.10M derived: sum of 3 quarters · filed 2026-08-06 | $8.67M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $2.50M 10-Q · filed 2026-05-06 | $4.70M derived: sum of 2 quarters · filed 2026-05-06 | $6.27M derived: sum of 3 quarters · filed 2026-05-06 | $7.97M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $3.77M derived: sum of 2 quarters · filed 2026-03-17 | $5.47M derived: sum of 3 quarters · filed 2026-08-06 | $6.50M 10-K · filed 2026-03-17 | |||
| 2025-09-30 | $1.57M 10-Q · filed 2025-11-05 | $3.27M derived: sum of 2 quarters · filed 2026-08-06 | $4.30M 10-Q · filed 2025-11-05 | $5.67M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $1.70M 10-Q · filed 2026-08-06 | $1.74M 10-Q · filed 2025-08-08 | $2.70M 10-Q · filed 2026-08-06 | $4.10M derived: sum of 3 quarters · filed 2026-08-06 | $4.66M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $900.00K 10-Q · filed 2026-05-06 | $2.40M derived: sum of 2 quarters · filed 2026-05-06 | $2.96M derived: sum of 3 quarters · filed 2026-05-06 | $3.52M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $2.06M derived: sum of 2 quarters · filed 2026-03-17 | $2.62M derived: sum of 3 quarters · filed 2026-03-17 | $2.60M 10-K · filed 2026-03-17 | |||
| 2024-09-30 | $560.00K 10-Q · filed 2025-11-05 | $1.12M derived: sum of 2 quarters · filed 2025-11-05 | $1.10M 10-Q · filed 2025-11-05 | $1.12M 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $563.00K 10-Q · filed 2025-08-08 | $600.00K 10-Q · filed 2025-08-08 | $563.00K 10-Q · filed 2024-08-08 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $0.00 10-K · filed 2026-03-17 | |||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | ||||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |